Your browser doesn't support javascript.
loading
Early Real-World Performance of the MiniMed™ 780G Advanced Hybrid Closed-Loop System and Recommended Settings Use in the United States.
Thrasher, James R; Arrieta, Arcelia; Niu, Fang; Cameron, Katherine R; Cordero, Toni L; Shin, John; Rhinehart, Andrew S; Vigersky, Robert A.
Afiliação
  • Thrasher JR; Arkansas Diabetes and Endocrinology Center, Little Rock, Arkansas, USA.
  • Arrieta A; Medtronic International Trading Sàrl, Tolochenaz, Switzerland.
  • Niu F; Medtronic Diabetes, Northridge, California, USA.
  • Cameron KR; Arkansas Diabetes and Endocrinology Center, Little Rock, Arkansas, USA.
  • Cordero TL; Medtronic Diabetes, Northridge, California, USA.
  • Shin J; Medtronic Diabetes, Northridge, California, USA.
  • Rhinehart AS; Medtronic Diabetes, Northridge, California, USA.
  • Vigersky RA; Medtronic Diabetes, Northridge, California, USA.
Diabetes Technol Ther ; 26(S3): 24-31, 2024 Mar.
Article em En | MEDLINE | ID: mdl-38377317
ABSTRACT

Background:

The MiniMed™ 780G system (MM780G) with Guardian™ 4 sensor includes a 100 mg/dL glucose target (GT) and automated insulin corrections up to every 5 min and was recently approved for use in the United States. In the present study, early real-world MM780G performance and the use of recommended system settings (100 mg/dL GT with an active insulin time of 2 h), by individuals with type 1 diabetes, were evaluated.

Methods:

CareLink™ personal data uploaded between the launch of the MM780G to August 22, 2023 were aggregated and underwent retrospective analysis (based on user consent) and if users had ≥10 days of continuous glucose monitoring (CGM) data. The 24-h day CGM metrics, including mean glucose, percentage of time spent in (%TIR), above (%TAR), and below (%TBR) target range (70-180 mg/dL), in addition to delivered insulin and closed-loop (CL) exits, were compared between an overall group (n = 7499) and individuals who used recommended settings (each, for >95% of the time). An analysis of the same metrics for MiniMed™ 770G system (MM770G) users (n = 3851) who upgraded to the MM780G was also conducted (paired t-test or Wilcoxon signed-rank test, P < 0.05 considered statistically significant).

Results:

For MM780G users, CGM use, and time in CL were >90% and all MM780G CGM metrics exceeded consensus-recommended goals. With recommended settings (22% of all users), mean %TIR and %TITR (70-140 mg/dL) were 81.4% and 56.4%, respectively. For individuals who upgraded from the MM770G, %TIR and %TITR increased from 73.2% to 78.3% and 45.8% to 52.6%, respectively, while %TAR reduced from 25.1% to 20.2% (P < 0.001, for all three). CL exits/week averaged <1, for all MM780G users.

Conclusions:

Early real-world MM780G use in the United States demonstrated a high percentage of time in range with low time above and below range. These outcomes are similar to those observed for real-world MM780G use in other countries.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Glicemia / Diabetes Mellitus Tipo 1 Limite: Humans País/Região como assunto: America do norte Idioma: En Revista: Diabetes Technol Ther Assunto da revista: ENDOCRINOLOGIA / TERAPEUTICA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Glicemia / Diabetes Mellitus Tipo 1 Limite: Humans País/Região como assunto: America do norte Idioma: En Revista: Diabetes Technol Ther Assunto da revista: ENDOCRINOLOGIA / TERAPEUTICA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos